Review anchor
ML-2
CELL-LINE · Homo sapiens
As of 2026-09-13
Evidence Snapshot
ML-2
CHEMBL614356
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats ML-2 as ChEMBL target CHEMBL614356. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL614356
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why ML-2 matters
ML-2 is reviewed as ML-2; the current evidence base includes 33 approved drugs, 192 compounds, and 30 assays, with lead potency reaching pChEMBL 10.7.
Protein context
ML-2
ML-2
Review this target as ML-2.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 33 approved drugs, 192 compounds, and 30 assays for this target. The dominant activity type is IC50. CHEMBL5428441 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL5428441 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
33 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why ML-2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
192
Total Compounds
30
Total Assays
33
Approved Drugs
IC50: 153.0, EC50: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5428441
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL5421145
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL5416318
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL4790597
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL566757
|
9.6 | IC50 | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
SELUMETINIB
CHEMBL1614701
|
2020 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
VENETOCLAX
CHEMBL3137309
|
2016 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
METHOTREXATE
CHEMBL34259
|
1953 |
Source Header